Imagine a medical breakthrough that could significantly reduce hospital visits and the time patients spend in care. This is precisely what semaglutide, a medication used for managing weight in individuals with cardiovascular disease, has shown in recent research. An exploratory analysis of the SELECT trial, published in JAMA Cardiology, reveals promising results indicating that semaglutide may lead to fewer hospital admissions and shorter stays for patients who are overweight or obese but do not have diabetes.
Involving a substantial cohort of 17,604 participants, with a median age of 61 years, and including 28% women, this study was conducted across 804 centers worldwide. These individuals were randomized to receive either a weekly subcutaneous injection of 2.4 mg of semaglutide or a placebo. The study spanned from October 2018 to March 2021, focusing primarily on the rates of hospital admissions and the duration of hospitalization.
The findings are significant. Over a median follow-up period of 42 months, the treatment group experienced a lower rate of hospitalizations for any reason compared to the placebo group—18.3 versus 20.4 per 100 patient-years, reflecting a mean ratio of 0.90 (with a confidence interval of 0.85-0.95), which was statistically significant (p<0.001). Moreover, the total number of days spent in the hospital was also reduced in those receiving semaglutide: 157.2 days versus 176.2 days for the control group, translating to a rate ratio of 0.89 (95% CI, 0.82-0.98; p=0.01).
These trends extended to hospitalizations related specifically to adverse events, further emphasizing semaglutide's potential benefits. The treatment group saw 15.2 admissions per 100 patient-years for adverse events compared to 17.1 for the placebo group (mean ratio of 0.89; 95% CI, 0.84-0.94; p<0.001), and fewer days hospitalized due to these events—137.6 days versus 153.9 days (rate ratio 0.89; 95% CI, 0.81-0.98; p=0.02).
The authors of the study noted, "We observed reductions in hospitalizations for various reasons, including cardiac issues, infections, respiratory problems, and even for surgical and medical procedures among those treated with semaglutide." This finding expands upon the previously recognized advantages of semaglutide regarding major adverse cardiovascular events, suggesting broader implications for clinical outcomes and healthcare systems alike.
In addition to the SELECT trial's insights, other recent publications in JAMA Network Open have explored related themes. One article examined bariatric surgery and GLP-1 receptor agonists (GLP1-RAs) in terms of their effectiveness in promoting fat loss. Authored by Zicheng Wang and colleagues, this study concluded that both approaches led to significant reductions in fat mass and fat-free mass over a two-year period, with bariatric surgery yielding greater relative decreases.
Another notable research letter by Yung-Chieh Huang and team highlighted a link between GLP1-RAs and decreased asthma exacerbations among adolescents aged 12 to 18 who are overweight or obese. Their findings suggest that a single class of medication might address both weight management and asthma risk, offering a dual benefit for this demographic.
For those interested in diving deeper into the intersection of obesity and cardiovascular health, the American College of Cardiology provides a Concise Clinical Guidance report aimed at optimizing medical weight management strategies (accessible here). Additionally, the Journal of the American College of Cardiology features a special collection on obesity, showcasing the latest articles, clinical trials, and expert video interviews (available here).
Overall, the emerging evidence surrounding semaglutide presents an exciting opportunity for improving the health outcomes of individuals with obesity and established cardiovascular diseases. As we continue to explore these innovative treatments, what are your thoughts on the implications of these findings? Do you agree that medications like semaglutide could reshape the landscape of hospital care for this population? Share your opinions below!
